Search

Displaying results 1981 - 1990 of 6198 in total
  1. Drug

    MK-4965

    go.drugbank.com/drugs/DB08460
    Experimental

    MK-4965 is an HIV-1 reverse transcriptase inhibitor.

  2. Indication

    Locally Advanced Breast Cancer (LABC)

    go.drugbank.com/conditions/DBCOND0034432
    Drugs: Anastrozole · Docetaxel · Elacestrant · Hyaluronidase (human recombinant) · Ixabepilone · Olaparib +4 more
    Synonyms: Ca breast, Ca breast - NOS
  3. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    of vitamin K. … [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]

    Mixtures: Decara K VegicapsCategories: Vitamin K
  4. Drug

    Interferon alfa-2a

    go.drugbank.com/drugs/DB00034
    ApprovedInvestigationalWithdrawn

    An oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

    Products: ROFERON - A ROCHE SOLUCION INYECTABLE 3 K/U.I.
  5. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

    Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN MONOCLONAL CK-301 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CK-301 .LAMBDA.-CHAIN, DIMER
  6. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]

  7. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  8. Drug

    Dichloralphenazone

    go.drugbank.com/drugs/DB01495
    ApprovedIllicit

    It is a US Schedule IV drug and its clinical use is limited.

  9. Drug

    Ceftriaxone

    go.drugbank.com/drugs/DB01212
    ApprovedInvestigational

    Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus.

    Products: CEFTRIAXONE FK ITALIA
  10. Target

    Vascular cell adhesion protein 1

    go.drugbank.com/bio_entities/BE0001114
    TargetHumans

    Cell adhesion glycoprotein predominantly expressed on the surface of endothelial cells that plays an important role in immune surveillance and inflammation (PubMed:31310649). Acts as a major regulator of leukocyte adhesion to the endothe...

    Synonyms: V-CAM 1